<DOC>
	<DOC>NCT01729351</DOC>
	<brief_summary>To evaluate the comparative effectiveness of extrafine hydrofluoroalkane beclometasone (EF HFA-BDP) and other inhaled corticosteroid (ICS) therapy commonly used in the UK, specifically fluticasone (FP) and non-extrafine (NEF) BDP (CFC-BDP and NEF HFA-BDP) in a UK primary care asthma population of current smokers.</brief_summary>
	<brief_title>Qvar Therapy in Smoking Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Aged 1670 years Current smokers explicitly coded in patient records or captured in patient questionnaires Evidence of asthma diagnosis and current therapy: ≥2 prescriptions for asthma at different points in time during the baseline year ± a diagnostic code for asthma Ongoing asthma therapy: ≥2 prescription for ICS during the outcome period (i.e. ≥1 prescription in addition to IPD prescription) ≥2 years continuous data (i.e. ≥1 year of baseline plus ≥1 year of outcome data) Patients will be excluded from the analysis if they have: Any chronic respiratory disease other than asthma Are prescribed: Maintenance oral steroid therapy during the baseline year Combination ICS/longacting beta agonist (LABA) therapy during baseline year or at IPD Multiple ICS prescriptions at IPD or immediately before .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Primary Care</keyword>
	<keyword>Particle size</keyword>
	<keyword>beclomethasone dipropionate</keyword>
	<keyword>Asthma Management</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Metered-Dose Inhaler</keyword>
	<keyword>Smoking</keyword>
</DOC>